PLSE 17.77 Pulse Biosciences, Inc.
| Range: | 3.78-22.69 | Vol Avg: | 182871 | Last Div: | 0 | Changes: | 1.48 |
| Beta: | 1.74 | Cap: | 1.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed May 18 2016 | Empoloyees: | 56 | ||
| CUSIP: | 74587B101 | CIK: | 0001625101 | ISIN: | US74587B1017 | Country: | US |
| CEO: | Mr. Burke T. Barrett | Website: | https://www.pulsebiosciences.com | ||||
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow